Allos Therapeutics, Inc. (Nasdaq: ALTH) announced the following for FOLOTYN's PROPEL trial in patients with relapsed or refractory peripheral T-cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE